$CAPR News

Capricor Therapeutics Announces FDA's Cellular, Tissue, And Gene Therapies Advisory Committee Intends To Call Advisory Committee Meeting To Discuss Capricor's BLA Of Deramiocel For Duchenne Muscular Dystrophy Treatment

Capricor Therapeutics To Present Data From Its Current HOPE-2 Open-Label Extension Trial Of Deramiocel For Duchenne Muscular Dystrophy At Parent Project Muscular Dystrophy 2026 Annual Conference

Capricor Therapeutics, Inc. (CAPR) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Capricor: I Rate It A Buy After Stress-Testing The Sell Thesis

HC Wainwright & Co. Reiterates Buy on Capricor Therapeutics, Maintains $60 Price Target

Capricor Therapeutics, Inc. (CAPR) Q1 2026 Earnings Call Transcript

Capricor Therapeutics Inc (NASDAQ:CAPR) Q1 Results Show EPS Miss as Market Awaits August PDUFA Date

Capricor Therapeutics Q1 2026 Earnings Call Transcript

Capricor Therapeutics Says NS Pharma Delays Could Threaten Access To Duchenne Therapy

Capricor Files Lawsuit And Seeks Preliminary Injunction In New Jersey Court On May 7, 2026; Alleges Fundamental Pricing Flaw In Agreement With Nippon Shinyaku; Alleges NS Pharma Failed To Prepare For Deramiocel Launch And Breached Agreement; Seeks To Rescind Agreement And Obtain Right To Distribute

Capricor Therapeutics Presented Data From HOPE-3 Deramiocel Treatment For Muscular Dystrophy Phase 3 Clinical Trial At The American Academy of Neurology 2026 Annual Meeting In Chicago, Illinois On April 21

Caprock Intersects 38.48 g/t Au over 1.6m Included Within a Broader Interval of 2.84 g/t over 23.2m at Destiny

Early Warning Press Release - Frank Guillemette Announces Completion of Acquisition of Common Shares of Caprock Mining Corp.

Capricor Therapeutics (CAPR) Reports Positive Phase 3 HOPE-3 Data and $318M 2025 Cash Balance

Is It Too Late To Reassess Capricor Therapeutics (CAPR) After Its Recent 130% Surge?

Capricor Therapeutics, Inc. (CAPR) Presents at 2026 MDA Clinical & Scientific Conference - Slideshow

Capricor: Moving To 'Buy' Rating As New PDUFA Date Is Set For Deramiocel

B. Riley Securities Maintains Buy on Capricor Therapeutics, Raises Price Target to $63

Capricor Therapeutics Stock Slides As Q4 Earnings Miss Estimates

Piper Sandler Reiterates Overweight on Capricor Therapeutics, Raises Price Target to $58